Cardinal Health, Inc. (CAH)

NYSE: CAH · USD

$244

-2.07 (-0.8%)· Recorded snapshot

英文原文ZH

翻译期间显示英文原文

此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

StockMarketAgent Research · Analyzed 2026-10-03

Our latest published analysis: CAH rated Hold

Cardinal Health, Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$244 / share

Potential value

$320 / share

Upside to FV

+6.9%

from $244

Moat

8/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$52.9B
Revenue (ttm)	254.2B
Net income (ttm)	1.7B
EPS (ttm)	$7.23
Shares out	231.6M
P/E (trailing)	33.8x
P/E (forward)	17.7x
Dividend	$2.06 (0.84%)
Volume	604,751
Beta	0.50

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 254.2B
Net income (ttm): 1.7B
EPS (ttm): $7.23
P/E (trailing): 33.8x
P/E (forward): 17.7x
Market cap: $52.9B

Item	P1	P2	P3	P4	P5	Trend
Period	2022-06-30	2023-06-30	2024-06-30	2025-06-30	2026-06-30	Trend
Revenue	$181.33B	$204.98B	$226.83B	$222.58B	$254.25B	+8.8%
Gross profit	$6.48B	$6.87B	$7.41B	$8.17B	$9.77B	+10.8%
Operating income	$-607.0M	$752.0M	$1.24B	$2.28B	$2.61B	—
Net income	$-938.0M	$330.0M	$852.0M	$1.56B	$1.71B	—
EPS (diluted)	$-3.37	$1.26	$3.45	$6.45	$7.23	—
EBITDA	$55.0M	$1.44B	$1.96B	$3.11B	$3.48B	+182.0%
R&D	—	—	—	—	—	—
SG&A	$4.51B	$4.80B	$5.00B	$5.38B	$6.13B	+8.0%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	卖出
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	卖出
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	强力买入
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	卖出
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	减持
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	减持

Base and Bull scenarios

Base55%

Price target

$244.05

+6.9% from spot

Cardinal Health executes steadily within the wholesale triopoly, expanding operating margins gradually from FY2026 through FY2027 and FY2028 toward terminal targets by FY2031. Revenue advances from reported FY2026 baseline through FY2027 and FY2028 consensus paths, while diluted EPS expands above reported historical levels through forward expectations, supported by ongoing share repurchases. This yields the composite Fair value of $244.05.

Revenue growth steadily expands across FY2027 and FY2028
Operating margin expands progressively across FY2027 and FY2028 toward long-term targets by FY2031
Reinvestment rate moderates from initial forecast years into steady state
Effective tax rate remains normalized across intermediate and terminal forecast years
Cost of capital reflects moderate equity risk premium and baseline discount rates

Bull20%

Price target

$320.21

+40.3% from spot

Consolidated operating margin expands toward peer levels matching McKesson and closing the gap with Cencora, driven by distribution automation efficiencies and specialty pharmaceutical mix growth. With strong cash generation sustaining share repurchases, diluted EPS reaches the upper tier of consensus expectations and fair value expands toward $320.21.

Operating margin expands toward wholesale peer levels by FY2028
Revenue growth accelerates supported by specialty pharmaceutical demand
Diluted EPS achieves the high end of consensus expectations by FY2028
Net share count reduction sustained at an accelerated pace annually

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($244.05). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	1.8%	2.0%	2.3%	2.5%	2.8%
6.2%	$252	$257	$263	$269	$276
6.7%	$241	$245	$249	$254	$259
7.2%	$231	$234	$244	$241	$246
7.7%	$222	$225	$228	$231	$234
8.2%	$215	$217	$220	$222	$225

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E17.7

P25 n/aP50 n/aP75 n/a

Trailing P/E30.8

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC18.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CAH indicators

Market & fundamental data

Available fields

285

Groups with data

Currency

USD

Showing 285 of 285 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000721371
Company name	Cardinal Health, Inc.
Country	United States
Country code	US
CUSIP number	14149Y108
Earnings date	2026-11-05
Earnings time	bmo
Employees	63,900
Employees change	6,200
Employees growth	10.75%
Enterprise value	$61.7B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	June
Founded	1979
In index	SP500
Industry	Medical Distribution
Is primary listing	Yes
Is SPAC	No
ISIN number	US14149Y1082
Last 10-K release date	2026-08-11
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split date	2001-04-23
Last stock split type	Forward
Market cap	$56.6B
Market cap category	Large-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$244.39
Price currency	USD
Sector	Healthcare
SIC code	5122
Stock price date	2026-10-28
Symbol	CAH
Tags	pharmaceuticals
U.S. state	Ohio
Website	https://www.cardinalhealth.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	22.32x
Average P/E ratio (10Y)	181.56x
Average P/E ratio (3Y)	34.74x
Average P/E ratio (5Y)	35.65x
Earnings yield	2.96%
EV/Earnings	36.02x
EV/EBIT	18.78x
EV/EBITDA	14.55x
EV/FCF	13.64x
EV/Sales	0.24x
FCF / EV yield	7.33%
FCF yield	7.99%
Forward EV/Sales	0.23x
Forward P/E	19.45x
Forward P/S	0.21x
Industry forward P/E	19.16x
Industry P/E	27.41x
Lynch fair value	$165.65
Lynch upside	-32.23%
P/(FCF - SBC) ratio	13.61x
P/(OCF - SBC) ratio	11.77x
P/E ratio	33.8x
P/FCF ratio	12.51x
P/OCF ratio	10.94x
P/S ratio	0.22x
PEG ratio	1.32x
Price/EBITDA ratio	13.34x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	1.29%
EBITDA margin	1.67%
Effective tax rate	21.57%
FCF margin	1.78%
Gross margin	3.84%
Operating margin	1.29%
Pretax margin	0.86%
Profit margin	0.67%
Profit per employee	$26,823
Profitable quarters	11
Profitable years	4
Revenue per employee	$4M
ROA	3.72%
ROA (5Y)	2.96%
ROCE	24.55%
ROIC	18.36%
ROIC (5Y)	15.17%
SBC / revenue	0.14%
Tax / revenue	0.18%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	12.09%
EPS growth (Q)	68.8%
EPS growth (QoQ)	-0.54%
EPS growth 10Y	5.28%
EPS growth 3Y	79.03%
EPS growth 5Y	28.3%
EPS growth quarters	1
EPS growth years	4
FCF growth	144.6%
FCF growth (Q)	10.87%
FCF growth (QoQ)	-14.85%
FCF growth 3Y	24.18%
FCF growth 5Y	17.4%
Gross profit growth	19.66%
Gross profit growth (Q)	16.26%
Gross profit growth 3Y	12.45%
Gross profit growth 5Y	7.6%
Net income growth	9.8%
Net income growth (Q)	66.53%
Net income growth (QoQ)	-0.25%
Net income growth 3Y	73.18%
Net income growth 5Y	22.91%
Net income growth quarters	1
Net income growth years	4
OCF growth	115.85%
OCF growth (Q)	11.32%
OCF growth (QoQ)	-7.19%
OCF growth 10Y	5.7%
OCF growth 3Y	22.08%
OCF growth 5Y	16.33%
Operating income growth	32.26%
Operating income growth (Q)	34.02%
Operating income growth 3Y	22.49%
Operating income growth 5Y	12.88%
Revenue growth	14.23%
Revenue growth (Q)	5.84%
Revenue growth (QoQ)	4.48%
Revenue growth 10Y	7.66%
Revenue growth 3Y	7.44%
Revenue growth 5Y	9.37%
Revenue growth quarters	6
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-649M
Depreciation and amortization	$956M
EBIT	$3.3B
EBITDA	$4.2B
EPS	$7.23
FCF per share	$19.54
Financing cash flow	$-1.6B
Free cash flow	$4.5B
Free cash flow minus SBC	$4.2B
Gross profit	$9.8B
Income taxes	$469M
Investing cash flow	$-2.6B
Net borrowing	$337M
Net cash flow	$982M
Net income	$1.7B
Operating cash flow minus SBC	$4.8B
Operating income	$3.3B
Revenue	$254.2B
Stock-based compensation	$367M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	5.02
Book value per share	$-12.37
Debt / EBITDA	2.2
Debt / FCF	2.21
Goodwill	$11.4B
Interest coverage	9.45
Long-term assets	$18.5B
Long-term liabilities	$16.1B
Net cash (debt)	$-5.1B
Net cash / market cap	-9.08%
Net debt / EBITDA	1.21
Net debt / FCF	1.14
Piotroski F-Score	7
Property, plant and equipment	$4B
Shareholders' equity	$-2.7B
Tangible book value	$-16.5B
Tangible book value per share	$-70.88
Total assets	$57.3B
Total cash	$4.9B
Total debt	$10B
Total liabilities	$60B
WACC	6.36%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	4.61
Current assets	$38.8B
Current liabilities	$43.9B
Current ratio	0.88
Inventory turnover	14.33
Net working capital	$-7.9B
Quick ratio	0.43
Working capital	$-5.2B
Working capital turnover	-66.25

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	2.07%
Dividend growth	1%
Dividend growth (10Y)	2.08%
Dividend growth (3Y)	1%
Dividend growth (5Y)	1%
Dividend growth years	1
Dividend payment date	2026-10-15
Dividend payment years	44
Dividend payout frequency	Quarterly
Dividend per share	$2.06
Dividend yield	0.84%
Ex-dividend date	2026-10-01
FCF payout ratio	10.56%
Last dividend	$0.52
Payout ratio	28.54%
Shareholder yield	2.91%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	226.69%
10Y return CAGR	15.71%
10Y total return	330.11%
150-day SMA	$223.20
15Y price change	443.64%
15Y return CAGR	14.82%
15Y total return	694.37%
1D price change	-0.84%
1M price change	10.96%
1M total return	11.22%
1W price change	-5.12%
1W total return	-5.12%
1Y price change	49.19%
1Y return CAGR	50.64%
1Y total return	50.59%
20-day SMA	$244.11
200-day SMA	$221.75
20Y price change	279.04%
20Y return CAGR	11.19%
20Y total return	733.89%
3M price change	6.55%
3M total return	6.79%
3Y price change	167.39%
3Y return CAGR	40.78%
3Y total return	179.1%
50-day SMA	$237.00
50-day SMA vs 200-day SMA	50over200
52-week high	$259.21
52-week high date	2026-10-22
52-week low	$161.64
52-week low date	2025-10-29
5Y price change	415.1%
5Y return CAGR	41.65%
5Y total return	470.2%
6M price change	20.77%
6M total return	21.31%
All-time high	$259.21
All-time high date	2026-10-22
All-time low	$0.99
All-time low date	1984-12-05
Average true range (ATR)	$5.35
Average volume	1.6M
Beta (1Y)	0
Beta (2Y)	0.3
Beta (5Y)	0.5
Change from 52-week high	-5.72%
Change from 52-week low	51.19%
Change from all-time high	-5.73%
Change from all-time low	24,466.7%
Change from open	-0.02%
Day's gap	-0.82%
Dollar volume	$147.8M
High price	$247.04
Low price	$243.83
Monthly RSI	69.02
Open price	$244.44
Position in 52-week range	17.45%
Premarket change	-0.17%
Premarket close	$246.45
Premarket price	$246.02
Premarket volume	1.2K
Previous close	$246.45
Price vs 150-day SMA	9.48%
Price vs 20-day SMA	0.1%
Price vs 200-day SMA	10.2%
Price vs 50-day SMA	3.11%
Relative volume	0.38
RSI	51.98
Sharpe ratio	1.39
Sharpe ratio (3Y)	1.31
Sharpe ratio (5Y)	1.34
Sortino ratio	2.77
Sortino ratio (3Y)	2.35
Sortino ratio (5Y)	2.37
Volume	604.8K
Weekly RSI	58.59
YTD price change	18.91%
YTD total return	20.04%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	231.1M
Float percentage	99.81%
Shares change (QoQ)	-0.42%
Shares change (YoY)	-2.07%
Shares held by insiders	0.08%
Shares held by institutions	90.6%
Shares outstanding	231.6M
Short % of float	3.19%
Short % of shares	3.18%
Short ratio	4.1 days

Deeper analysis on CAH

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this CAH report

What is the latest published CAH stock rating?

Cardinal Health, Inc. is shown with Hold in the latest published report, analyzed 2026-10-03. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CAH analysis?

The full latest published report, analyzed 2026-10-03, lives at /stocks/CAH/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for CAH?

The latest published report analyzed 2026-10-03 gives CAH a fair value of USD 244 and a potential value of USD 320. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the CAH page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-03). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

HoldCAH · Fair value $244+6.9%

Read full analysis →

Category	Score	Reading
Valuation	6.0
Management	9.5
Balance Sheet	3.0
Profitability	5.0
Revenue Growth	6.0
Risk Assessment	5.5
Competitive Moat	8.0
Earnings Quality	9.0
Capital Efficiency	6.5

Cardinal Health, Inc. (CAH)

Our latest published analysis: CAH rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · CAH

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All CAH indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CAH

Frequently asked questions

评级历史